---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-25-000002"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:32:49.070876+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna: 2024 sales $3.0-3.1B; 2025 revenue guided $1.5-2.5B, down ~40%; CMV trial misses early efficacy

## Summary
- 2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.
- 2025 revenue guidance $1.5-2.5B (mostly H2); expects year-end cash ~$6.0B.
- Accelerating cost cuts: $1B cash-cost reduction in 2025, additional $0.5B in 2026.
- CMV vaccine Phase 3 DSMB: early efficacy not met; study continues blinded. Final data expected 2025.
- Next-gen COVID BLA accepted (PDUFA May 31, 2025); RSV vaccine for high-risk adults filed; flu/COVID combo filed.

## SEC filing metadata
- accession: 0001682852-25-000002
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000002/0001682852-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000002/mrna-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-25-000002
- JSON: https://secwatch.observer/filing/0001682852-25-000002.json
- Plain text: https://secwatch.observer/filing/0001682852-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.